Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (551-560 of 934) with videos related to

Pageof 94
Sort By:
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
Journal of the American Heart Association|October 26, 2017
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) TrialChristina L Fanola, David A Morrow, Christopher P Cannon, et al.
The American Journal of Cardiology|September 5, 2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)C Michael Gibson, Hung Q Ly, Sabina A Murphy, et al.
Kidney International|March 13, 2018
Efficacy and safety of lipid lowering by alirocumab in chronic kidney diseasePeter P Toth, Jamie P Dwyer, Christopher P Cannon, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
Nature Communications|February 16, 2016
Gut immunity in a protochordate involves a secreted immunoglobulin-type mediator binding host chitin and bacteriaLarry J Dishaw, Brittany Leigh, John P Cannon, et al.
Pageof 94

Showing results (551-560 of 934) with videos related to

Sort By:
Pageof 94
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
Journal of the American Heart Association|October 26, 2017
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) TrialChristina L Fanola, David A Morrow, Christopher P Cannon, et al.
The American Journal of Cardiology|September 5, 2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)C Michael Gibson, Hung Q Ly, Sabina A Murphy, et al.
Kidney International|March 13, 2018
Efficacy and safety of lipid lowering by alirocumab in chronic kidney diseasePeter P Toth, Jamie P Dwyer, Christopher P Cannon, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
Nature Communications|February 16, 2016
Gut immunity in a protochordate involves a secreted immunoglobulin-type mediator binding host chitin and bacteriaLarry J Dishaw, Brittany Leigh, John P Cannon, et al.
Pageof 94